GSK plc (GSK) on Tuesday said the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Exdensur for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.
The approval was based on data from the Phase III SWIFT and ANCHOR trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen.
Exdensur has also received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) and is under regulatory review in other markets, including the United States, Japan and China. Decisions from regulatory authorities are anticipated from December 2025 through the first half of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.